Publications
AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease
Mohile, S,
Blaum, CS,
Abadir, PM,
Dale, W,
Forman, DE,
Fung, C,
Holmes, HM,
Moslehi, J,
Mustian, KM,
Rich, MW,
Whitson, HE,
J Am Geriatr Soc, 2022 Oct; DOI:10.1111/jgs.17921 Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Singh, N,
Temin, S,
Baker, S,
Blanchard, E,
Brahmer, JR,
Celano, P,
Duma, N,
Ellis, PM,
Elkins, IB,
Haddad, RY,
Hesketh, PJ,
Jain, D,
Johnson, DH,
Leighl, NB,
Mamdani, H,
Masters, G,
Moffitt, PR,
Phillips, T,
Riely, GJ,
Robinson, AG,
Rosell, R,
Schiller, JH,
Schneider, BJ,
Spigel, DR,
Jaiyesimi, IA,
J Clin Oncol, 2022 Oct; DOI:10.1200/JCO.22.00825 First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Bauer, T,
Cho, BC,
Heist, R,
Bazhenova, L,
Werner, T,
Goel, S,
Kim, D-W,
Adkins, D,
Carvajal, RD,
Alva, A,
Eaton, K,
Wang, J,
Liu, Y,
Yan, X,
Christensen, J,
Neuteboom, S,
Chao, R,
Pant, S,
Invest New Drugs, 2022 Oct; DOI:10.1007/s10637-022-01274-y Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Makrakis, D,
Talukder, R,
Lin, GI,
Diamantopoulos, LN,
Dawsey, S,
Gupta, S,
Carril-Ajuria, L,
Castellano, D,
de Kouchkovsky, I,
Koshkin, VS,
Park, JJ,
Alva, A,
Bilen, MA,
Stewart, TF,
McKay, RR,
Tripathi, N,
Agarwal, N,
Vather-Wu, N,
Zakharia, Y,
Morales-Barrera, R,
Devitt, ME,
Cortellini, A,
Fulgenzi, CAM,
Pinato, DJ,
Nelson, A,
Hoimes, CJ,
Gupta, K,
Gartrell, BA,
Sankin, A,
Tripathi, A,
Zakopoulou, R,
Bamias, A,
Murgic, J,
Fröbe, A,
Rodriguez-Vida, A,
Drakaki, A,
Liu, S,
Lu, E,
Kumar, V,
Lorenzo, GD,
Joshi, M,
Isaacsson-Velho, P,
Buznego, LA,
Duran, I,
Moses, M,
Jang, A,
Barata, P,
Sonpavde, G,
Yu, EY,
Montgomery, RB,
Grivas, P,
Khaki, AR,
Clin Genitourin Cancer, 2022 Oct; DOI:10.1016/j.clgc.2022.06.001 Rectal Cancer, Version 2.2022
Benson, AB,
Venook, AP,
Al-Hawary, MM,
Azad, N,
Chen, Y-J,
Ciombor, KK,
Cohen, S,
Cooper, HS,
Deming, D,
Garrido-Laguna, I,
Grem, JL,
Gunn, A,
Hecht, JR,
Hoffe, S,
Hubbard, J,
Hunt, S,
Jeck, W,
Johung, KL,
Kirilcuk, N,
Krishnamurthi, S,
Maratt, JK,
Messersmith, WA,
Meyerhardt, J,
Miller, ED,
Mulcahy, MF,
Nurkin, S,
Overman, MJ,
Parikh, A,
Patel, H,
Pedersen, K,
Saltz, L,
Schneider, C,
Shibata, D,
Skibber, JM,
Sofocleous, CT,
Stotsky-Himelfarb, E,
Tavakkoli, A,
Willett, CG,
Gregory, K,
Gurski, L,
J Natl Compr Canc Netw, 2022 Oct; DOI:10.6004/jnccn.2022.0051 Variation in the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features
Chen, DW,
Rob, FI,
Mukherjee, R,
Giordano, TJ,
Haymart, MR,
Banerjee, M,
J Clin Endocrinol Metab, 2022 Sep; DOI:10.1210/clinem/dgac466 Abstract A007: Resident memory T cells express PD-1 in high grade liposarcoma
Angeles, CV,
Han, J,
Wilkoswki, J,
Bresler, S,
Clinical Cancer Research, 2022 Sep; DOI:10.1158/1557-3265.sarcomas22-a007 Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy
Eng, SE,
Basasie, B,
Lam, A,
John Semmes, O,
Troyer, DA,
Clarke, GD,
Sunnapwar, AG,
Leach, RJ,
Johnson-Pais, TL,
Sokoll, LJ,
Chan, DW,
Tosoian, JJ,
Siddiqui, J,
Chinnaiyan, AM,
Thompson, IM,
Boutros, PC,
Liss, MA,
Prostate Cancer Prostatic Dis, 2022 Sep; DOI:10.1038/s41391-022-00591-w Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition.
Udden, SN,
Wang, Q,
Kumar, S,
Malladi, VS,
Wu, S-Y,
Wei, S,
Posner, BA,
Geboers, S,
Williams, NS,
Liu, Y,
Sharma, JK,
Mani, RS,
Malladi, S,
Parra, K,
Hofstad, M,
Raj, GV,
Larios, JM,
Jagsi, R,
Wicha, MS,
Park, BH,
Gupta, GP,
Chinnaiyan, AM,
Chiang, C-M,
Alluri, PG,
JCI Insight, 2022 Sep; DOI:10.1172/jci.insight.151851 JS04.6.A The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Liu, I,
Jiang, L,
Samuelsson, E,
Salas, SM,
Hack, O,
Jeong, D,
Shaw, M,
Englinger, B,
LaBelle, J,
Ernst, K,
Palova, H,
Pokorna, P,
Sterba, J,
Slaby, O,
Geyeregger, R,
Jones, D,
Koschmann, C,
Svedlund, J,
Resnick, A,
Diaz, A,
Haberler, C,
Czech, T,
Slavc, I,
Cotter, J,
Ligon, K,
Alexandrescu, S,
Yung, W,
Arrillaga-Romany, I,
Suva, M,
Beck, A,
Gojo, J,
Monje, M,
Nilsson, M,
Filbin, M,
Neuro-Oncology, 2022 Sep; DOI:10.1093/neuonc/noac174.021 Perfusion and diffusion-weighted imaging parameters: Comparison between pre-and postbiopsy MRI for high-grade glioma
Kurokawa, R,
Baba, A,
Kurokawa, M,
Capizzano, A,
Ota, Y,
Kim, J,
Srinivasan, A,
Moritani, T,
Medicine (Baltimore), 2022 Sep; DOI:10.1097/MD.0000000000030183 Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [<sup>18</sup>F]FDG: version 1.0
Piccardo, A,
Albert, NL,
Borgwardt, L,
Fahey, FH,
Hargrave, D,
Galldiks, N,
Jehanno, N,
Kurch, L,
Law, I,
Lim, R,
Lopci, E,
Marner, L,
Morana, G,
Young Poussaint, T,
Seghers, VJ,
Shulkin, BL,
Warren, KE,
Traub-Weidinger, T,
Zucchetta, P,
Eur J Nucl Med Mol Imaging, 2022 Sep; DOI:10.1007/s00259-022-05817-6 Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal, JM,
Cianciolo Cosentino, C,
Yadavilli, S,
Zhang, J,
Laternser, S,
Bonner, ER,
Prasad, R,
Dawood, AA,
Lobeto, N,
Chin Chong, W,
Biery, MC,
Myers, C,
Olson, JM,
Panditharatna, E,
Kritzer, B,
Mourabit, S,
Vitanza, NA,
Filbin, MG,
de Iuliis, GN,
Dun, MD,
Koschmann, C,
Cain, JE,
Grotzer, MA,
Waszak, SM,
Mueller, S,
Nazarian, J,
Neuro Oncol, 2022 Sep; DOI:10.1093/neuonc/noac041 Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Powles, T,
Tomczak, P,
Park, SH,
Venugopal, B,
Ferguson, T,
Symeonides, SN,
Hajek, J,
Gurney, H,
Chang, Y-H,
Lee, JL,
Sarwar, N,
Thiery-Vuillemin, A,
Gross-Goupil, M,
Mahave, M,
Haas, NB,
Sawrycki, P,
Burgents, JE,
Xu, L,
Imai, K,
Quinn, DI,
Choueiri, TK,
KEYNOTE-564 Investigators, Array,
Lancet Oncol, 2022 Sep; DOI:10.1016/S1470-2045(22)00487-9 Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan
Strohbehn, GW,
Cooperrider, JH,
Yang, D,
Fendrick, AM,
Ratain, MJ,
Zaric, GS,
Value Health Reg Issues, 2022 Sep; DOI:10.1016/j.vhri.2022.01.007 Transcutaneous Electrical Acustimulation Improves Irritable Bowel Syndrome With Constipation by Accelerating Colon Transit and Reducing Rectal Sensation Using Autonomic Mechanisms
Huang, Z,
Lin, Z,
Lin, C,
Chu, H,
Zheng, X,
Chen, B,
Du, L,
Chen, JDZ,
Dai, N,
Am J Gastroenterol, 2022 Sep; DOI:10.14309/ajg.0000000000001882 Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma
Li, M-X,
Lopez-Aguiar, AG,
Poultsides, G,
Rocha, F,
Weber, S,
Fields, R,
Idrees, K,
Cho, C,
Maithel, SK,
Zhang, X-F,
Pawlik, TM,
J Surg Oncol, 2022 Sep; DOI:10.1002/jso.26928 Differentiation of Skull Base Chondrosarcomas, Chordomas, and Metastases: Utility of DWI and Dynamic Contrast-Enhanced Perfusion MR Imaging
Ota, Y,
Liao, E,
Capizzano, AA,
Baba, A,
Kurokawa, R,
Kurokawa, M,
Srinivasan, A,
AJNR Am J Neuroradiol, 2022 Sep; DOI:10.3174/ajnr.A7607 Intracranial paragangliomas versus schwannomas: Role of dynamic susceptibility contrast perfusion and diffusion MRI.
Ota, Y,
Liao, E,
Capizzano, AA,
Baba, A,
Kurokawa, R,
Kurokawa, M,
Srinivasan, A,
J Neuroimaging, 2022 Sep; DOI:10.1111/jon.13002 Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer
Achreja, A,
Yu, T,
Mittal, A,
Choppara, S,
Animasahun, O,
Nenwani, M,
Wuchu, F,
Meurs, N,
Mohan, A,
Jeon, JH,
Sarangi, I,
Jayaraman, A,
Owen, S,
Kulkarni, R,
Cusato, M,
Weinberg, F,
Kweon, HK,
Subramanian, C,
Wicha, MS,
Merajver, SD,
Nagrath, S,
Cho, KR,
DiFeo, A,
Lu, X,
Nagrath, D,
Nat Metab, 2022 Sep; DOI:10.1038/s42255-022-00636-3 De Novo Neuroendocrine Features in Prostate Cancer.
Abdulfatah, E,
Fine, SW,
Lotan, TL,
Mehra, R,
Hum Pathol, 2022 Sep; DOI:10.1016/j.humpath.2022.07.002 p53 null phenotype is a "positive result" in urothelial carcinoma in situ
Sangoi, AR,
Chan, E,
Abdulfatah, E,
Stohr, BA,
Nguyen, J,
Trpkov, K,
Siadat, F,
Hirsch, M,
Falzarano, S,
Udager, AM,
Kunju, LP,
Mod Pathol, 2022 Sep; DOI:10.1038/s41379-022-01062-2 Adolescent and parent perspectives on genomic sequencing to inform cancer care
Sedig, LK,
Jacobs, MF,
Mody, RJ,
Le, LQ,
Bartnik, NJ,
Gornick, MC,
Anderson, B,
Chinnaiyan, AM,
Roberts, JS,
Pediatr Blood Cancer, 2022 Sep; DOI:10.1002/pbc.29791 Exploring variation in the receipt of recommended active surveillance for men with favorable-risk prostate cancer
Radhakrishnan, A,
Wallner, LP,
Skolarus, TA,
George, AK,
Rosenberg, BH,
Abrahamse, P,
Hawley, ST,
J Urol, 2022 Sep; DOI:10.1097/JU.0000000000002734 A pilot multi-institutional study to evaluate the accuracy of a supine MRI based guidance system, the Breast Cancer Locator™, in patients with palpable breast cancer
Barth, RJ,
Krishnaswamy, V,
Rooney, TB,
Fox, MJ,
Burman, HEG,
Rosenkranz, KM,
Gass, J,
Bronfine, BI,
Angeles, CV,
Paulsen, KD,
Surg Oncol, 2022 Sep; DOI:10.1016/j.suronc.2022.101843 